Simultaneous Methemoglobinemia and Hemolytic Anemia Related to Trimethoprim-sulfamethoxazole and Phenazopyridine
International Journal of Medical Toxicology and Forensic Medicine,
Vol. 14 No. 1 (2024),
4 February 2024
https://doi.org/10.32598/ijmtfm.v14i1.43201
Abstract
Background: Methemoglobinemia manifests with cyanosis but no respiratory distress. Many substances implicated in methemoglobinemia also are known to cause either drug-induced hemolysis or oxidative stress on erythrocytes, leading to hemolysis. This case report described a patient presenting acutely with both cyanosis and jaundice.
Case Presentation The patient is a 76-year-old female with a history of chronic obstructive pulmonary disease and a recently diagnosed urinary tract infection (UTI) who presented to the emergency department with urinary frequency and dysuria. She had recently been started on trimethoprim-sulfamethoxazole (TMP-SMX) and phenazopyridine for her UTI. On physical exam, she had both cyanosis and jaundice, giving her skin a dull, gray color. She had hypoxia to 75% oxygen saturation, which did not remarkably respond to supplemental oxygen. She also had hyperbilirubinemia and anemia. Laboratory errors confounded the evaluation; however, there was high concern for methemoglobinemia, and empiric treatment was initiated. Methemoglobinemia was later confirmed and the patient improved, although she required multiple blood transfusions. After removing the offending agents, treating the methemoglobinemia, and providing supportive care for her hemolytic anemia, she improved and was discharged home.
Conclusion: Although methemoglobinemia has a classic presentation of cyanosis without respiratory distress, additional coincident pathologies can easily confuse the clinical picture. Understanding the pathophysiology of methemoglobinemia is key to understanding why our patient also developed hemolysis. When cyanosis and jaundice are both present, simultaneous management of methemoglobinemia and hemolytic anemia may be needed. Special attention to glucose 6-phosphate dehydrogenase status is required in these circumstances to avoid patient harm with methylene blue.
- Hemolytic anemia
- Methemoglobinemia
- Cyanosis
- Jaundice
- Oxidation
How to Cite
References
Iolascon, A., Bianchi, P., Andolfo, I., Russo, R., Barcellini, W., Fermo, E., ... & SWG of red cell and iron of EHA and EuroBloodNet. (2021). Recommendations for diagnosis and treatment of methemoglobinemia. American Journal of Hematology, 96(12), 1666-1678.
Sonck, E., Bourmanne, E., Bruteyn, J., & Dolip, W. (2022). Methemoglobinemia due to use of poppers: a case report. Journal of Medical Case Reports, 16(1), 1-4.
Jacob, G., Schorr, M., & Moist, L. M. (2022). Methemoglobinemia in a 28-year-old woman treated with dapsone. CMAJ, 194(30), E1062-E1065.
Gehrs, B. C., & Friedberg, R. C. (2002). Autoimmune hemolytic anemia. American journal of hematology, 69(4), 258-271.
Saleh, D., Lucyk, S., & McGillis, E. (2022). Methemoglobinemia caused by sodium nitrite overdose. CMAJ, 194(30), E1066-E1067.
Rehman, A., Shehadeh, M., Khirfan, D., & Jones, A. (2018). Severe acute haemolytic anaemia associated with severe methaemoglobinaemia in a G6PD-deficient man. Case Reports, 2018, bcr-2017.
Patnaik, S., Natarajan, M. M., James, E. J., & Ebenezer, K. (2014). Methylene blue unresponsive methemoglobinemia. Indian journal of critical care medicine: peer-reviewed, official publication of Indian Society of Critical Care Medicine, 18(4), 253.
Golden, P. J., & Weinstein, R. (1998). Treatment of high‐risk, refractory acquired methemoglobinemia with automated red blood cell exchange. Journal of Clinical Apheresis: The Official Journal of the American Society for Apheresis, 13(1), 28-31.
- Abstract Viewed: 584 times
- pdf Downloaded: 491 times